|
Re: Zenith Abstract at AACR 2017 Meeting April 1-5
|
5
|
Zenith Epigenetics
|
Mar 08, 2017 01:34AM
|
|
Happy New Year
|
5
|
Zenith Epigenetics
|
Jan 01, 2019 03:53AM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
5
|
Resverlogix Corp.
|
Sep 06, 2017 02:05PM
|
|
Re: ... clarification update...
|
5
|
Resverlogix Corp.
|
Jun 11, 2018 04:09PM
|
|
Re: Looking at the chart...introducing the bullish channel
|
5
|
Resverlogix Corp.
|
Sep 21, 2018 09:42PM
|
|
Re: Too good "to be allowed" to be true?
|
5
|
Resverlogix Corp.
|
Dec 31, 2017 04:55AM
|
|
Re: The Pfizer connection...
|
5
|
Resverlogix Corp.
|
Nov 30, 2018 10:06PM
|
|
Re: 2019 Potential Events
|
5
|
Resverlogix Corp.
|
Sep 17, 2019 11:04AM
|
|
Re: Will Apabetalone end up in China first?
|
5
|
Resverlogix Corp.
|
Aug 04, 2018 11:01AM
|
|
Re: iceberg or ice cube?
|
5
|
Resverlogix Corp.
|
May 17, 2017 01:36PM
|
|
Secondary indications
|
5
|
Resverlogix Corp.
|
Jan 24, 2019 12:25PM
|
|
Re: BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency
|
5
|
Resverlogix Corp.
|
Dec 05, 2017 06:18PM
|
|
Thank you to those who voted
|
5
|
Resverlogix Corp.
|
Apr 11, 2017 03:56PM
|
|
Re: A few things
|
5
|
Resverlogix Corp.
|
Oct 17, 2017 08:22PM
|
|
Re: Equity financing
|
5
|
Zenith Epigenetics
|
Jun 25, 2018 09:01PM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
5
|
Resverlogix Corp.
|
May 11, 2017 11:50PM
|
|
Re: Third Eye Loan
|
5
|
Resverlogix Corp.
|
Dec 28, 2018 11:23AM
|
|
Re: Scenario Analysis on end of BETonMACE Phase 3
|
5
|
Resverlogix Corp.
|
Apr 15, 2019 04:27PM
|
|
Re: Could BETonMACE Cognition Sub-Study be presented at AAIC this month?
|
5
|
Resverlogix Corp.
|
Jul 03, 2019 02:36PM
|
|
Re: New RVX Tweet
|
5
|
Resverlogix Corp.
|
Sep 04, 2020 07:38PM
|
